VPIM
EGRX

Vanguard Personalized Indexing Management’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Vanguard Personalized Indexing Management’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-15,530
Closed -$57.9K – 1906
2024
Q3 		$57.9K Buy
15,530
+1,901
+14% +$9.07K ﹤0.01% 1665
2024
Q2 		$76.3K Buy
+13,629
New +$59.4K ﹤0.01% 1559

Other funds holding EGRX

XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
SLG
Stanley-Laman Group Berwyn, Pennsylvania $814M AUM 40.24% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
AIC
Archer Investment Corporation Carmel, Indiana $469M AUM 19.1% 1-Year Est. Return
Credit Agricole
Credit Agricole Montrouge Cedex, France $38.1B AUM
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

Vanguard Personalized Indexing Management's EGRX Position: Q4 2024 in Review

Vanguard Personalized Indexing Management sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q4 2024, closing a stake of 15,530 shares — an estimated $57.9K sold.

Vanguard Personalized Indexing Management first reported a position in EGRX in Q2 2024 and held it in 2 quarters. The position peaked at $76.3K in Q2 2024. 9 funds tracked by Wall St. Rank hold EGRX as of Q4 2024.

  • Vanguard Personalized Indexing Management reported no remaining Eagle Pharmaceuticals, Inc. position as of Q4 2024 after selling out during the quarter.
  • Vanguard Personalized Indexing Management sold 15,530 Eagle Pharmaceuticals, Inc. shares in Q4 2024, an estimated $57.9K.
  • Vanguard Personalized Indexing Management first reported a position in Eagle Pharmaceuticals, Inc. in Q2 2024 and held it in 2 quarters.
  • Vanguard Personalized Indexing Management's Eagle Pharmaceuticals, Inc. position peaked at $76.3K in Q2 2024.
  • 9 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q4 2024.

Based on Vanguard Personalized Indexing Management's 13F filing for Q4 2024, filed 10 Feb 2025.